Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Leukemia|January 22, 1998
A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cellsF W Cremer, K Kiel, C Sucker, et al.
Bone Marrow Transplantation|November 18, 2000
Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myelomaF W Cremer, E Ehrbrecht, K Kiel, et al.
British Journal of Haematology|August 25, 1999
Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantationC Rottenburger, K Kiel, T Bösing, et al.
Bone Marrow Transplantation|June 18, 1999
Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantationK Kiel, F W Cremer, C Rottenburger, et al.
Human Genetics|September 2, 2004
A large MSH2 Alu insertion mutation causes HNPCC in a German kindredMatthias Kloor, Christian Sutter, Nicolas Wentzensen, et al.
Orphanet Journal of Rare Diseases|October 24, 2020
Revesz syndrome revisitedMichael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, et al.
British Journal of Cancer|September 14, 2006
Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgeryA Zahlten-Hinguranage, H Goldschmidt, F W Cremer, et al.
Drugs Under Experimental and Clinical Research|January 1, 1985
Comparative in vitro studies with 4-quinolone antimicrobialsD Felmingham, M D O'Hare, M J Robbins, et al.
British Journal of Haematology|March 2, 1999
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell contentM T Voso, S Hohaus, M Moos, et al.
Annals of Hematology|March 22, 2002
Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantationC Gemmel, F W Cremer, M Weis, et al.
Pageof 8